Document Detail


Threshold concentration of ozone causing an increase in bronchial reactivity in humans and adaptation with repeated exposures.
MedLine Citation:
PMID:  6169298     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
To determine the lowest concentration of ozone that causes an increase in bronchial reactivity to histamine and to determine whether adaptation to this effect of ozone develops with repeated exposures, we studied 19 healthy adult subjects. Bronchial reactivity was assessed by measuring the rise in specific airway resistance (delta SRaw) produced by inhalation of 10 breaths of histamine aerosol (1.6% solution). In 5 subjects, bronchial reactivity was determined at 9:00 and 11:30 A.M. on 4 consecutive days without exposure to ozone (Group I). In 7 other subjects (Group II), bronchial reactivity was assessed at 9:00 and 11:30 A.M. on 3 consecutive days, and subjects were exposed to 0.2 ppm of ozone from 9:30 to 11:30 A.M. on the third day. Seven additional subjects (Group III) had bronchial reactivity assessed in a similar fashion for 2 days and then again on 3 consecutive days of 2-h exposures to 0.4 ppm of ozone. Pre-exposure bronchial reactivity of the groups was the same, and no change in bronchial reactivity occurred in the group tested repeatedly but not exposed to ozone. An increase in delta SRaw provoked by histamine was noted after the first exposure to 0.4 ppm but not to 0.2 ppm of ozone (p less than 0.025). With 3 repeated 2-h exposures to 0.4 ppm on consecutive days, however, the delta SRaw produced by histamine progressively decreased, returning to pre-exposure values after the third exposure. Our results indicate that the threshold concentration of ozone causing an increase in bronchial reactivity in healthy human subjects is between 0.2 and 0.4 ppm, and that adaptation to this effect of ozone develops with repeated exposures. The threshold concentration of ozone identified in other studies as causing changes in symptoms, lung volumes, or airway resistance was also between 0.2 and 0.4 ppm, and the time course of the development of tolerance to ozone in these other studies was similar to hat observed in our study. We propose that the appearance of symptoms, changes in pulmonary function, and the increase in bronchial reactivity may be caused by a change in the activity of afferent nerve endings in the airway epithelium.
Authors:
M J Dimeo; M G Glenn; M J Holtzman; J R Sheller; J A Nadel; H A Boushey
Related Documents :
2240838 - Ozone concentration and pulmonary response relationships for 6.6-hour exposures with fi...
482928 - Shark heart mitochondria: effects of external osmolality on respiration.
22890428 - Kinematic and kinetic synergies of the lower extremities during the pull in olympic wei...
10982578 - Randomised trial investigating effect of a novel nicotine delivery device (eclipse) and...
22574708 - Knee joint neuromuscular activation performance during muscle damage and superimposed f...
18636328 - The epidemiology of obesity and gastrointestinal and other diseases: an overview.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  The American review of respiratory disease     Volume:  124     ISSN:  0003-0805     ISO Abbreviation:  Am. Rev. Respir. Dis.     Publication Date:  1981 Sep 
Date Detail:
Created Date:  1981-11-18     Completed Date:  1981-11-18     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0370523     Medline TA:  Am Rev Respir Dis     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  245-8     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adaptation, Physiological
Adult
Airway Resistance / drug effects
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Hypersensitivity
Drug Tolerance*
Female
Histamine Release / drug effects*
Humans
Hypersensitivity, Immediate / chemically induced*
Lung Volume Measurements
Male
Ozone / adverse effects*
Grant Support
ID/Acronym/Agency:
HL-00130/HL/NHLBI NIH HHS; HL-07185/HL/NHLBI NIH HHS; HL-24136/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
10028-15-6/Ozone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Participation of a pure neuronal mechanism in the control of gonadal functions.
Next Document:  Flushing reactions: consequences and mechanisms.